FDA Clears Medtronic Hugo Robotic Surgery System for Urologic Procedures

Reuters12-04 05:30
FDA Clears Medtronic Hugo Robotic Surgery System for Urologic Procedures

Medtronic plc has received clearance from the U.S. Food and Drug Administration (FDA) for its Hugo™ robotic-assisted surgery (RAS) system for use in urologic surgical procedures. This FDA clearance allows U.S. hospitals and surgeons new options in expanding robotic surgery programs and increasing patient access to minimally invasive care. The approval follows the successful Expand URO clinical study, which demonstrated the system's safety and effectiveness. Medtronic plans to seek additional indications for the Hugo RAS system in the U.S. for general and gynecologic surgical procedures in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via PR Newswire (Ref. ID: CG38589) on December 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment